TRAJ17: A Protein Essential for T Cell Function (G28738)

Target Name: TRAJ17

NCBI ID: G28738

TRAJ17

Other Name(s): T cell receptor alpha joining 17

TRAJ17: A Protein Essential for T Cell Function

T cell receptor alpha-joining 17 (TRAJ17) is a protein that is expressed in T cells, a type of immune cell that plays a crucial role in the immune system. T cells are responsible for recognizing and responding to foreign substances in the body, and their activity is critical for maintaining the immune system's ability to protect the body against infection and disease.

TRAJ17 is a type of protein that is made up of several domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is the part of the protein that is involved in interactions with other cells or cell processes, while the transmembrane domain is responsible for the protein's movement into and out of the cell membrane. The intracellular domain is the part of the protein that interacts with inside the cell, where it plays a role in regulating various cellular processes.

One of the key functions of T cells is their ability to recognize and respond to specific antigens. These antigens can be proteins or molecules that are specific to the body's cells, or they can be foreign substances like viruses or bacteria. When an antigen binds to a T cell, it can trigger a signaling cascade that tells the cell to divide, differentiate, and activate. This is how T cells are able to recognize and respond to foreign substances in the body.

TRAJ17 is involved in the process of T cell receptor (TCR) joining, which is the step in the signaling cascade where the T cell recognizes and binds to an antigen. TCR joining involves the interaction between the T cell receptor and the protein on the surface of the antigen. This interaction is critical for triggering the signaling cascade that tells the cell to divide, differentiate, and activate.

TRAJ17 is a protein that is expressed in T cells, and it plays a crucial role in the process of T cell receptor joining. It is made up of several domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the protein's interactions with other cells or cell processes, while the transmembrane domain is responsible for the protein's movement into and out of the cell membrane. The intracellular domain is responsible for the protein's interactions with inside the cell.

TRAJ17 is a protein that is critical for the function of T cells, and it is a potential drug target or biomarker. Studies have shown that TRAJ17 is involved in the process of T cell receptor joining, and that it plays a role in regulating the activity of T cells. This suggests that TRAJ17 may be a useful target for drugs that are designed to stimulate or inhibit T cell activity. Additionally, TRAJ17 may also be a useful biomarker for tracking the effectiveness of T cell-based therapies.

In conclusion, T cell receptor alpha-joining 17 (TRAJ17) is a protein that is expressed in T cells and plays a crucial role in the process of T cell receptor joining. It is made up of several domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the protein's interactions with other cells or cell processes, while the transmembrane domain is responsible for the protein's movement into and out of the cell membrane. The intracellular domain is responsible for the protein's interactions with inside the cell. TRAJ17 is a potential drug target or biomarker, and its role in the function of T cells makes it an important target for researchers to study. Further studies are needed to fully understand the role of TRAJ17 in the immune system and its potential as a drug or biomarker.

Protein Name: T Cell Receptor Alpha Joining 17

The "TRAJ17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets